Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the New Drug Application (NDA) of its internally-developed IL-17-targeting monoclonal antibody gumokimab (AK111) has been ...

The drugmaker sees additional growth opportunities in ophthalmology and neuromuscular disorders, Chief Medical Officer ...

A major research breakthrough on Parkinson's disease revealed that an already FDA-approved cancer drug could help stem the ...